BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. Hepatol Res 2018;48:E61-7. [PMID: 28628718 DOI: 10.1111/hepr.12927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Starlinger P, Ubl DS, Hackl H, Starlinger J, Nagorney DM, Smoot RL, Habermann EB, Cleary SP. Combined APRI/ALBI score to predict mortality after hepatic resection. BJS Open 2021;5:zraa043. [PMID: 33609383 DOI: 10.1093/bjsopen/zraa043] [Reference Citation Analysis]
2 Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res 2019;49:919-28. [PMID: 30969006 DOI: 10.1111/hepr.13348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
3 Kariyama K, Nouso K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, Toyoda H, Tada T, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kudo M, Kumada T. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer 2020;9:734-43. [PMID: 33442542 DOI: 10.1159/000508971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, Takai A, Takahashi K, Taura K, Seno H. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2021;28:498-507. [PMID: 33787071 DOI: 10.1002/jhbp.954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Kawaguchi T, Shimose S, Yamamura S, Nakano D, Tanaka M, Torimura T. Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then. Ann Transl Med 2020;8:1045. [PMID: 33145264 DOI: 10.21037/atm-2020-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Tsai PH, Chou SJ, Lee RC, Hou MC, Huo TI. Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res 2021. [PMID: 34038019 DOI: 10.1111/hepr.13671] [Reference Citation Analysis]
8 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K, Seno H. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers (Basel). 2019;12:49. [PMID: 31877859 DOI: 10.3390/cancers12010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
9 Takigawa A, Sakamori R, Tahata Y, Yoshioka T, Yamada R, Kodama T, Hikita H, Yakushijin T, Ohkawa K, Hiramatsu N, Mita E, Hagiwara H, Ito T, Imai Y, Tatsumi T, Takehara T. Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller. Dig Dis Sci 2022. [PMID: 35353331 DOI: 10.1007/s10620-022-07455-2] [Reference Citation Analysis]
10 Pereyra D, Rumpf B, Ammann M, Perrodin SF, Tamandl D, Haselmann C, Stift J, Brostjan C, Laengle F, Beldi G, Gruenberger T, Starlinger P. The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. Ann Surg Oncol 2019;26:791-9. [PMID: 30617869 DOI: 10.1245/s10434-018-07125-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
11 Li W, Han J, Xie G, Xiao Y, Sun K, Yuan K, Wu H. Laparoscopic versus open mesohepatectomy for patients with centrally located hepatocellular carcinoma: a propensity score matched analysis. Surg Endosc 2019;33:2916-26. [PMID: 30498855 DOI: 10.1007/s00464-018-6593-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kawaguchi T, Honda A, Sugiyama Y, Nakano D, Tsutsumi T, Tahara N, Torimura T, Fukumoto Y. Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis. Hepatol Res 2021;51:1207-18. [PMID: 34534392 DOI: 10.1111/hepr.13714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
14 Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer 2019;8:121-9. [PMID: 31019902 DOI: 10.1159/000488778] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
15 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, Takai A, Takahashi K, Seno H. Branched‐chain amino acid to tyrosine ratio is an essential pre‐treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2020;27:913-21. [DOI: 10.1002/jhbp.821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]